NCT00867737

Brief Summary

The objectives of this study are to measure Impulse Oscillometry (IOS) in patients with asthma extensively at baseline in patients with mild-to-moderate asthma, treated with as-needed short acting beta agonist only, to measure respiratory resistance and small airway dysfunction accurately and precisely at baseline, from which to measure onset of action of Advair MDI in comparison with that of Symbicort MDI. Initial screening will assess IOS resistance and small airway dysfunction and its response to short acting beta agonist (SABA). Patients will be selected from among those who manifest a 40% improvement in small airway function assessed by IOS low frequency reactance after SABA compared to baseline. After screening, patients will be randomized to receive either Advair or Symbicort; and will be assessed at randomization before and at several intervals after initial dosing, up to 4 hours. Patients will return again 4 weeks after randomization for extended IOS (and spirometry) testing as done at randomization.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at P25-P50 for phase_4 asthma

Timeline
Completed

Started Sep 2008

Shorter than P25 for phase_4 asthma

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2008

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

March 23, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 24, 2009

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2009

Completed
Last Updated

March 24, 2009

Status Verified

March 1, 2009

Enrollment Period

1 year

First QC Date

March 23, 2009

Last Update Submit

March 23, 2009

Conditions

Keywords

AsthmaForced OscillationImpulse OscillometryElectrical-equivalent respiratory system model

Outcome Measures

Primary Outcomes (1)

  • Integrated low frequency reactance improvement after initial dosing

    5, 20, 40, 60, 120, and 240 min

Secondary Outcomes (2)

  • Frequency-dependence of Resistance (R5-R20) after initial dosing

    5, 20, 40, 60, 120, and 240 min

  • Model-derived estimates of Large and Small Airway Resistance and Compliance, and their changes after initial dosing

    5, 20, 40, 60, 120, and 240 min

Study Arms (2)

Advair 115/21 MDI

EXPERIMENTAL

Advair HFA 115/21 MDI Intervention = initiate intervention after screening

Drug: Advair HFA MDI 115/21

2 = Symbicort 160/4.5

ACTIVE COMPARATOR

Symbicort initiated after screening

Drug: Symbicort 160/4.5 pMDI

Interventions

Two puffs from MDI twice daily for 4 weeks

Also known as: Advair = fluticasone proprionate plus salmeterol
Advair 115/21 MDI

Symbicort 160/4.5 pMDI Two puffs from MDI twice daily for 4 weeks

Also known as: Symbicort = budesonide plus formoterol fumarate
2 = Symbicort 160/4.5

Eligibility Criteria

Age12 Years - 45 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Clinical diagnosis of asthma
  • Asthma symptoms controlled by short-acting beta agonist as-needed
  • Age 12-45 years

You may not qualify if:

  • Severe asthma
  • use of oral or inhaled corticosteroids within 30 days of screening

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Allergy and Asthma Center of El Paso

El Paso, Texas, 79925, United States

RECRUITING

MeSH Terms

Conditions

Asthma

Interventions

Salmeterol XinafoateFormoterol Fumarate

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

AlbuterolEthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesPhenethylaminesEthylamines

Study Officials

  • Rogelio Menendez, MD

    Allergy and Asthma Center of El Paso

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Rogelio Menendez, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 23, 2009

First Posted

March 24, 2009

Study Start

September 1, 2008

Primary Completion

September 1, 2009

Study Completion

September 1, 2009

Last Updated

March 24, 2009

Record last verified: 2009-03

Locations